Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1

Molecular Pharmacology

Volumn 81, Issue 5, 2012, Pages 748-758

  Cruickshanks, Nichola ^a   Hamed, Hossein A ^a   Bareford, M Danielle ^a   Poklepovic, Andrew ^a   Fisher, Paul B ^b   Grant, Steven ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LAPATINIB; OBATOCLAX; PHOSPHATASE; PROTEIN BCL XL; PROTEIN MCL 1; TENSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL KILLING; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME 10; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; INHIBITION KINETICS; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL; TUMOR CELL;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; BCL-X PROTEIN; CELL LINE, TUMOR; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3;

EID: 84859939822     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.077586     Document Type: Article

References (39)

1. Alva AS, Gultekin SH, and Baehrecke EH (2004) Autophagy in human tumors: cell survival or death? Cell Death Differ 11:1046-1048. (Pubitemid 39232364)
2. Awada A, Saliba W, and Bozovic-Spasojevic I (2011) Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer. Drugs Today (Barc) 47:335-345.
3. Berezowska S and Schlegel J (2011) Targeting ErbB receptors in high-grade glioma. Curr Pharm Des 17:2468-2487.
4. Bigner SH and Vogelstein B (1990) Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma. Brain Pathol 1:12-18.
5. Depowski PL, Rosenthal SI, and Ross JS (2001) Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14:672-676. (Pubitemid 32667211)
6. Duhem-Tonnelle V, Bièche I, Vacher S, Loyens A, Maurage CA, Collier F, Baroncini M, Blond S, Prevot V, and Sharif A (2010) Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133- positive putative cancer stem cells. J Neuropathol Exp Neurol 69:606-622.
7. Eulitt PJ, Park MA, Hossein H, Cruikshanks N, Yang C, Dmitriev IP, Yacoub A, Curiel DT, Fisher PB, and Dent P (2011) Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biol Ther 10:1290-1305.
8. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello- Gruszfeld A, Crown J, Chan A, Kaufman B, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743. (Pubitemid 46021510)
9. Graf MR, Jia W, Johnson RS, Dent P, Mitchell C, and Loria RM (2009) Autophagy and the functional roles of Atg5 and beclin-1 in the anti-tumor effects of 3βandrostene 17α diol neuro-steriod on malignant glioma cells. J Steroid Biochem Mol Biol 115:137-145.
10. Hamed HA, Yacoub A, Park MA, Eulitt P, Sarkar D, Dimitrie IP, Chen CS, Grant S, Curiel DT, Fisher PB, and Dent P (2010) OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biol Ther 9:526-536.
11. Hippert MM, O'Toole PS, and Thorburn A (2006) Autophagy in cancer: good, bad, or both? Cancer Res 66:9349-9351.
12. Höland K, Salm F, and Arcaro A (2011) The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors. Curr Cancer Drug Targets 11:894-918.
13. Hynes NE and Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors [published erratum appears in Nat Rev Cancer 5:580, 2005]. Nat Rev Cancer 5:341-354. (Pubitemid 40637826)
14. Jia W, Loria RM, Park MA, Yacoub A, Dent P, and Graf MR (2010) The neurosteroid, 5-androstene 3â,17á diol; induces endoplasmic reticulum stress and autophagy through PERK/eIF2á signaling in malignant glioma cells and transformed fibroblasts. Int J Biochem Cell Biol 42:2019-2029.
15. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, and Larijani B (2008) HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PloS ONE 3:e2881.
16. Leslie NR and Foti M (2011) Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci 32:131-140.
17. Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, et al. (2008) Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol 74:807-822.
18. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, and Dent P (2009) Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 8:2084-2096.
19. Mathew R, Karantza-Wadsworth V, and White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7:961-967. (Pubitemid 350165856)
20. Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, and KolchW(2011) Raf family kinases: old dogs have learned new tricks. Genes Cancer 2:232-260.
21. Mehrpour M, Esclatine A, Beau I, and Codogno P (2010) Autophagy in health and disease. 1. Regulation and significance of autophagy: an overview. Am J Physiol Cell Physiol 298:C776-C785.
22. Miller KD (2004) The role of ErbB inhibitors in trastuzumab resistance. The Oncologist 9:16-19.
23. Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, and Dent P (2010) Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 10:903-917.
24. Onvani S, Etame AB, Smith CA, and Rutka JT (2010) Genetics of medulloblastoma: clues for novel therapies. Expert Rev Neurother 10:811-823.
25. Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, and Dent P (2010) Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther 9:2220-2231.
26. Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, et al. (2009) MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther 8:1280-1291.
27. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, et al.(2008) Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 7:1648-1662.
28. Parkin DM, Bray F, Ferlay J, and Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. (Pubitemid 40372904)
29. Pattingre S, Espert L, Biard-Piechaczyk M, and Codogno P (2008) Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 90:313-323. (Pubitemid 351181247)
30. Robins HI, Chang S, Butowski N, and Mehta M (2007) Therapeutic advances for glioblastoma multiforme: current status and future prospects. Curr Oncol Rep 9:66-70. (Pubitemid 46075636)
31. Schmidt AL, Brunetto AL, Schwartsmann G, Roesler R, and Abujamra AL (2010) Recent therapeutic advances for treating medulloblastoma: focus on new molecular targets. CNS Neurol Disord Drug Targets 9:335-348.
32. Seminario MC, Precht P, Wersto RP, Gorospe M, and Wange RL (2003) PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression. Oncogene 22:8195-8204. (Pubitemid 37487310)
33. Tao RH and Maruyama IN (2008) All EGF(ErbB) receptors have preformed homoand heterodimeric structures in living cells. J Cell Sci 121:3207-3217.
34. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, Polli JW, Castellino S, Rubin SD, Lockman PR, Steeg PS, and Smith QR. (2012) Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 29:770-781.
35. van Delft MF and Huang DC (2009) How the BCL-2 family of proteins interact to regulate apoptosis. Cell Res 16:203-213.
36. Wang CW and Klionsky DJ (2003) The molecular mechanism of autophagy. Mol Med 9:65-76.
37. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, and Heasley LE (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 5:e14117.
38. Yoshimori T and Noda T (2008) Toward unraveling membrane biogenesis in mammalian autophagy. Curr Opin Cell Biol 20:401-407.
39. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, et al. (2008) Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 14:5385-5399